Status:
COMPLETED
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
Lead Sponsor:
China Medical University Hospital
Conditions:
Advanced Lung Adenocarcinoma
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become standard practice for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutation. EGFR-TKIs involving Afati...
Detailed Description
Lung cancer is the leading cause of cancer deaths worldwide. According to National Comprehensive Cancer Network (NCCN) Guidelines, EGFR-TKIs have become standard practice for advanced NSCLC with EGFR ...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed diagnosis of locally advanced or metastatic lung adenocarcinoma with EGFR mutations,
- Patients with an Eastern Cooperative Oncology Group performance status score of 0-2,
- Patients receiving afatinib as first-line treatment to ensure a shorter time to observe skin adverse effects of any grade,
- Patients with measurable disease evaluated by the Response Evaluation Criteria in Solid Tumors (version 1.1),
- Patients with brain metastases were included after adequate treatment.
Exclusion
Key Trial Info
Start Date :
May 12 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05204758
Start Date
May 12 2016
End Date
February 28 2021
Last Update
January 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.